<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472027</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-145-1</org_study_id>
    <nct_id>NCT03472027</nct_id>
  </id_info>
  <brief_title>Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma</brief_title>
  <official_title>A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-145 (JSC BIOCAD, Russia) in Patients With Unresectable/Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics,
      Pharmacodynamics, Safety, and Immunogenicity of BCD-145 (JSC BIOCAD, Russia) Monotherapy in
      Patients with Unresectable/Metastatic Melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Actual">December 4, 2018</completion_date>
  <primary_completion_date type="Actual">September 11, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>85 days</time_frame>
    <description>The Investigators defined Dose-Limiting Toxicities (DLTs) as
any treatment-related adverse events of grade 3 or greater,
grade 3 or greater immune-mediated toxic effects (defined as an inflammatory process that compromised the function of any organ and was not attributable to another cause) that had the potential to be life threatening with continuation of therapy,
immune-mediated toxic effects that did not resolve or improved to grade 2 or less within 14 days of onset</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody levels of BCD-145</measure>
    <time_frame>85 days</time_frame>
    <description>Binding and neutralizing anti-drug antibody levels of BCD-145</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Objective Response</measure>
    <time_frame>85 days</time_frame>
    <description>Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as ≥30% decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study ≥4 weeks after initial documentation of response.
Pilot efficacy assessment is not the primary objective of this study and will be conducted by surrogate endpoints describing the direct antitumor effect of the drug.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>BCD-145 Monotherapy Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-145 Monotherapy Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-145 Monotherapy Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-145 Monotherapy Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-145 Monotherapy Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-145</intervention_name>
    <description>Anti-CTLA-4 monoclonal antibody, IV infusion</description>
    <arm_group_label>BCD-145 Monotherapy Dose Level 1</arm_group_label>
    <arm_group_label>BCD-145 Monotherapy Dose Level 2</arm_group_label>
    <arm_group_label>BCD-145 Monotherapy Dose Level 3</arm_group_label>
    <arm_group_label>BCD-145 Monotherapy Dose Level 4</arm_group_label>
    <arm_group_label>BCD-145 Monotherapy Dose Level 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient provides a written informed consent and is able to follow the requirements of
             the Protocol;

          2. Age ≥ 18 years

          3. Histologically confirmed (well-documented test results; preferably, block specimens
             available) unresectable (stage III/IV) or metastatic (stage IV) melanoma (the drug
             will be used as the first of subsequent therapy lines);

          4. ECOG score of 0 to 2;

          5. Measurable disease (at least one lesion) according to RECIST v1.1 ;

          6. Resolved toxicity events from the previous therapy or adverse consequences of surgical
             interventions to ≤ grade 1 CTCAE v. 4.03, except for chronic/irreversible adverse
             events not affecting the safety of the study therapy (e.g. alopecia);

          7. No severe pathology of organs or systems;

          8. Life expectancy of at least 16 weeks from the screening;

          9. Patients of childbearing potential enrolled in the study must agree to use reliable
             contraception methods throughout the study period, beginning 2 weeks before the
             inclusion in the study and up to 8 weeks after the last dose of BCD-145.

        Exclusion Criteria:

          1. Severe concomitant illnesses or life-threatening consequences (including
             pleural/pericardial/peritoneal effusion that requires medical intervention , pulmonary
             lymphangitis, or involvement of &gt;50% renal parenchyma);

          2. Brain metastases ;

          3. Severe cardiovascular disorders within 6 months before screening;

          4. Autoimmune diseases;

          5. Conditions requiring steroids or any other immunosuppressants;

          6. Blood disorders: ANC ≤1,500/mm3; platelets ≤100,000/mm3; or Hb ≤90 g/L;

          7. Renal function impairment: creatinine ≥1.5 × ULN;

          8. Hepatic function impairment: bilirubin ≥1.5 × ULN; AST and ALT ≥2.5 × ULN (5 × ULN for
             patients with liver metastases), AlkPh ≥ 5 × ULN;

          9. Endocrine disorders: abnormal thyroid hormones

         10. Prior anticancer treatment within 28 days before starting the study drug (surgery,
             radiation therapy , or chemotherapy);

         11. Known history of more than 6 lines of systemic anticancer chemotherapy (including
             neoadjuvant and adjuvant CTs);

         12. Prior treatment with anti-PD1/PDL1 agents or CTLA4 inhibitors;

         13. Concurrent malignancy except for radically resected cervical carcinoma in situ or
             radically resected basal cell/squamous cell carcinoma;

         14. Conditions limiting patient's ability to follow the Protocol requirements (dementia,
             neurological or psychiatric disorders, drug or alcohol abuse, etc.);

         15. Simultaneous participation in any other clinical trial; participation in other
             clinical trials within 30 days before inclusion in the present study; previous
             participation in the present study.

         16. Acute infections or active chronic infections;

         17. Documented hepatitis B, active hepatitis C, HIV or syphilis infection;

         18. Intravenous administration of the drug is impossible;

         19. Intravenous administration of contrast agents is impossible;

         20. Hypersensitivity to any component of BCD-145.

         21. Known history of hypersensitivity to monoclonal antibodies;

         22. Pregnancy or breastfeeding;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman A Ivanov, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vice President R&amp;D, JSC BIOCAD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>N.N. Blokhin National Medical Research Center of Oncology</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC &quot;Modern Medical Technologies&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.N. Petrov National Medical Research Center of Oncology</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

